A practical reference on hGH fragment: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-04-04. Anything still debated is marked as such rather than presented as settled.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Based on the C-terminal region of human growth hormone. |
| Amino acid length | 16 residues | Often described as hGH fragment 176-191. |
| Appearance | Lyophilized powder | Typically white to off-white; exact appearance depends on grade. |
| Solubility | Soluble in water | Aqueous solubility depends on pH, ionic strength, and preparation. |
| Typical storage | -20 °C or lower | Lyophilized peptide is usually kept cold and dry; solutions may require freezing. |
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
==== Impact of UDI ==== The years following Rhodesia's UDI saw an unfolding series of economic, military, and political pressures placed on the country that eventually brought about majority rule, a totality of these factors rather than any one the reason for introducing change. In 2005, a conference at the London School of Economics that discussed Rhodesia's independence concluded that UDI was sparked by an existing racial conflict complicated by Cold War intrigues. Critics of UDI maintained that Ian Smith intended to safeguard the privileges of an entrenched colonial ruling class at the expense of the impoverished black population. Smith defended his actions by claiming that the black Rhodesian majority was too inexperienced at the time to participate in the complex administrative process of what was, by contemporary African standards, a reasonably industrialised state. At large, UDI further hardened the white population's attitudes towards majority rule and relations with the UK. A significant majority of white Rhodesian residents were either British immigrants or of British ancestry, and many held a special affection for the British Empire. However, the UK's refusal to grant them independence on their terms further confirmed their opposition to a political settlement on British terms, and fed their negative attitudes towards British interference in Rhodesian politics at large.
=== Salmonella outbreaks === Tomatoes have been linked to multiple Salmonella food poisoning outbreaks in the US. One in 2008 caused the temporary removal of tomatoes from stores and restaurants across the United States and parts of Canada. In 2022 and 2023, an outbreak of Salmonella Senftenberg ST14 affected the US and 12 countries in Europe.
== History == Founder Duane Sorenson and Stumptown Coffee Roasters have been labeled as part of the third wave of coffee movement. Sorenson and his employees visited coffee farms in person and reportedly paid high prices for beans, occasionally three or four times the fair trade price. He once set the record for highest price ever paid for coffee beans. Sorenson also offered atypical perks to his employees such as paying for a compilation album to be produced of their various bands, and hiring a full-time on-staff massage therapist. Stumptown received the Roaster of the Year 2006, an award from a technical trade magazine called Roast Magazine In January 2014, the company began selling coffee, pre-mixed with milk, in grocery stores. In 2015, Stumptown Coffee Roasters was bought by Peet's Coffee for an undisclosed amount.
Sources: en.wikipedia.org
=== Double-hydrogen rearrangement === The “1,5 ” hydrogen shift cause transfer of two γ- hydrogen to two radical sites on two different unsaturated atoms. The same requirements for McLafferty rearrangement apply to double-hydrogen rearrangement. This reaction is observed for three unsaturated functional groups, namely thioesters, esters and amides.
== See also == RO5073012 – TAAR1 weak partial agonist RO5166017 – TAAR1 partial or full agonist RO5203648 – TAAR1 partial agonist RO5256390 – TAAR1 partial or full agonist EPPTB – TAAR1 antagonist/inverse agonist
=== Music === TikTok has been noted by many media outlets as having a major influence in the music industry. American artist Lil Nas X notably rose to fame after his song "Old Town Road" went viral on TikTok in 2019. He acknowledged the platform's influence in popularizing the song, saying "[TikTok] really boosted the song ... I credit them a lot". Doja Cat has also been noted as an artist who achieved mainstream popularity thanks to her success on TikTok. Insider noted in 2020 that "one of the most popular, pervasive dances of all time" from TikTok was set to Say So, which became her first no.1 hit on the Billboard Hot 100. Pitchfork also noted Doja Cat's "astonishing, unprecedented TikTok reign", saying that before her fame on TikTok, "many people didn't fully register Doja Cat as a star". When it was launched, TikTok allowed users to upload videos that ranged from 3 seconds to 1 minute. The short video length limit led to users making sped-up versions of songs to use in their videos. This allowed them to fit more of the song in their video. Some artists, including SZA and Steve Lacy, released official sped-up versions of their songs after unofficial sped-up remixes of their songs went viral on the platform. TikTok has also helped popularize older songs. Fleetwood Mac's song Dreams re-entered the Billboard Hot 100 over 40 years after its release after a video that featured the song went viral on the platform. Dan Whateley from Insider noted that songs could "rise up organically on the app even if they've been outside the mainstream for decades".
Sources: en.wikipedia.org
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.
No. It represents only a short portion of the hGH sequence and lacks the full hormone's structure. As a result, its biological activity and regulatory status differ from those of prescription hGH.
The exact peptide is not typically described as a circulating hormone; it is a synthetic construct based on a natural sequence. Fragments of hGH can exist in laboratory or metabolic contexts, but AOD-9604 itself is manufactured for research.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.